Viatris price to free cash flow VTRS

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Oct 23, 2026: 10.6×
5-year median: 5.8×
Against its 5-year history: 95th; percentile: 0 is its lowest day, 100 its highest
5-year range: 3.4× to 11.4×
Peer median: 21.4×

Viatris' price to free cash flow is 10.6× as of Oct 23, 2026.

That is above its 5-year median of 5.8×, higher than on 95% of days in the last 5 years.

Over that time it ranged from 3.4× in Sep 2022 to 11.4× in Jul 2026.

The median for 10 healthcare stocks of a similar size is 21.4×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.6×	7.8×	11.4×
2025	8.5×	4.6×	8.5×
2024	7.6×	5.5×	8.2×
2023	6.2×	4.4×	6.4×
2022	4.7×	3.4×	5.5×
2021	4.9×	4.4×	5.1×

Against its peers

Companies in Healthcare nearest Viatris' size, closest first, today.

Company	Price to free cash flow
VTRSViatris	10.6×
THCTenet Healthcare	7.2×
STESTERIS	24.5×
ZBHZimmer Biomet	12.3×
MEDPMedpace	26.4×
INCYIncyte	12.2×
RVTYRevvity	31.7×
UTHRUnited Therapeutics	23.1×
LHLabcorp	23.1×
DGXQuest Diagnostics	19.8×
EXELExelixis	13.6×
Peer median	21.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Viatris

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.